There are a number of reasons that research peptides are labeled “not for human consumption.” To explain in full would require multiple pages, as this is a multifaceted issue involving multiple factors relating to the F.D.A. and Big Pharma that most of the general public is unaware of. We opted to condense it down to the primary elements to the best of our ability:

The biggest factor? The fact that the F.D.A. charges millions of dollars to consider medications for its approval process: not just a prohibitive factor for most peptide companies, but an absolute impossibility.

Next, to meet the size and scope of the mandatory preclinical (animal) and clinical (human) research trials requires hundreds of thousands to millions of dollars on top of the multi-million dollars for the approval funding. Easy to meet for the limitless pockets of Big Pharma, utterly impossible for the little guys. This is not to say that these companies or their partners are distributing unevaluated drugs to the public- there are many studies which prove the safety and efficacy of these drugs, just not on the scale required by the F.D.A. 

The composition of many peptides disqualifies them for patent protection, since they are usually comprised of proteins which are naturally present in the human body. The inability to patent these drugs makes them even less appealing to the profit-driven pharmaceutical industry. 

Finally, there are many instances in which doctors prescribe drugs “off-label,” which accomplish the same objective as their peptide counterparts. “Off-label” refers to the practice of doctors prescribing drugs for a purposes other than what the F.D.A. initially approved them for, broadening the competition with the major players even further.

Reputable peptide companies are a safe, effective alternative to their unreasonably overpriced counterparts from Big Pharma. We hold the safety of our customers in the highest regard, and send all batches to a third party lab to verify both their sterility and content prior to distribution.